ONLINE FIRST (FREE ACCESS) "ICU TOOLBOX" TOPICAL COLLECTION Editorial Monitoring cardiac output De Backer D., Hajjar L. and Monnet X. "MY GREEN ICU" COLLECTION CorrespondenceHow a green team can rapidly lower the carbon footprint of paracetamol route use in intensive careGisbert-Mora C. et al LATEST ARTICLES Original Noninvasive ventilation on reintubation in patients with obesity and hypoxemic respiratory failure following abdominal surgery: a ...

Original Investigation  September 25, 2024 Fever Prevention in Patients With Acute Vascular Brain Injury: The INTREPID Randomized Clinical Trial David M. Greer, Raimund Helbok, Neeraj Badjatia, et al JAMA. Published online September 25, 2024. doi:10.1001/jama.2024.14745 Key Points Question  Is an automated surface temperature management device effective in prevention of fever in patients with ac...

Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050 GBD 2021 Antimicrobial Resistance Collaborators Lancet 2024; 404: 1199-1226 Summary Background Antimicrobial resistance (AMR) poses an important global health challenge in the 21st century. A previous study has quantified the global and regional burden of AMR for 2019, followed with additional publications that provided more detailed estimates for sev...

ORIGINAL ARTICLE Beta-Blocker Interruption or Continuation after Myocardial Infarction Johanne Silvain, Guillaume Cayla, Emile Ferrari, et al N Engl J Med Published August 30, 2024 DOI: 10.1056/NEJMoa2404204 Abstract BACKGROUND The appropriate duration of treatment with beta-blocker drugs after a myocardial infarction is unknown. Data are needed on the safety and efficacy of the interruption of long-term beta-blocker...

ORIGINAL ARTICLE Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk Gerald F. Watts, Robert S. Rosenson, Robert A. Hegele, et al N Engl J Med Published September 2, 2024 DOI: 10.1056/NEJMoa2409368 Abstract BACKGROUND Persistent chylomicronemia is a genetic recessive disorder that is classically caused by familial chylomicronemia syndrome (FCS), but it also has multifactorial causes. The disorder is associated with the risk of rec...

ORIGINAL ARTICLE Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype David J. Jackson, Michael E. Wechsler, Daniel J. Jackson, et al N Engl J Med Published September 9, 2024 DOI: 10.1056/NEJMoa2406673 Abstract BACKGROUND Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals. METHODS In these phase 3A, randomized, placebo-contro...

ORIGINAL ARTICLE Ponsegromab for the Treatment of Cancer Cachexia John D. Groarke, Jeffrey Crawford, Susie M. Collins, et al N Engl J Med DOI: 10.1056/NEJMoa2409515 Abstract BACKGROUND Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a circulating cytokine, is elevated in cancer cachexia. In a small, open-label, phase 1b study involving patients with can...

ORIGINAL ARTICLE Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis Bruce E. Sands, Brian G. Feagan, Laurent Peyrin-Biroulet, et al N Engl J Med 2024;391:1119-1129 DOI: 10.1056/NEJMoa2314076 Abstract BACKGROUND Tulisokibart is a tumor necrosis factor–like cytokine 1A (TL1A) monoclonal antibody in development for the treatment of moderately to severely active ulcerative colitis. A genetic-based diagnostic test was design...

ORIGINAL ARTICLE Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B Adam Cuker, Kaan Kavakli, Laurent Frenzel, et al N Engl J Med 2024;391:1108-1118 DOI: 10.1056/NEJMoa2302982 Abstract BACKGROUND Fidanacogene elaparvovec, an adeno-associated virus (AAV) gene-therapy vector for hemophilia B containing a high-activity human factor IX variant (FIX-R338L/FIX-Padua), was associated with sustained factor IX activity in a phase 1–2a study...

ORIGINAL ARTICLE Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection Shunying Zhao, Yunxiao Shang, Yong Yin, et al N Engl J Med 2024;391:1096-1107 DOI: 10.1056/NEJMoa2313551 Abstract BACKGROUND Respiratory syncytial virus (RSV) is a leading cause of severe illness in infants, with no effective treatment. Results of a phase 2 trial suggested that ziresovir may have efficacy in the treatment of infants hospitalized with RSV infe...